Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...

Alpelisib is an orally bioavailable, α-selective PI3K inhibitor and degrader that showed efficacy and a manageable safety profile in combination with fulvestrant in the phase 3 SOLAR-1 study of ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

A novel inhibitor-loaded bilayer hybrid system based on the LDH inner layer and MOF outer layer is designed on an aluminum alloy 2A12 surface to improve corrosion performance. The hybrid film system ...

Research led by Samsung Medical Center finds breast cancer survivors exhibit an 8% lower risk of Alzheimer's dementia (AD) ...

Aromatase inhibitors (AIs) have emerged as the standard therapy for postmenopausal patients with estrogen/progesterone receptor-positive breast cancer. As adjuvant therapy, treatment is typically ...

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Image courtesy of Syngenta Group Metproxybicyclone’s has been distinguished as the fourth generation of ACCase-inhibitors, an important class of herbicides. Scientists precisely designed this ...